INS and Hypoglycemia: Over a median follow-up period of 8 months, the use of tirzepatide in adults with T1D was therefore associated with significant weight loss, along with significant reduction in daily insulin requirements and improvement of glucose control and cardiometabolic parameters, without reported serious adverse events (including severe hypoglycemia and DKA) [128].